Cliff Bentz
Trade Performance Intelligence
Score: 4/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
1 flagThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
4 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Treat and Reduce Obesity Act of 2025
The Treat and Reduce Obesity Act of 2025 (S.1973) is in early legislative stages, aiming to expand Medicare coverage for obesity treatments, including GLP-1 agonists and intensive behavioral therapy. This bill, if enacted, would significantly increase the total addressable market for pharmaceutical companies producing obesity drugs and manufacturers of related medical devices. Companies like Eli Lilly and Company ($LLY) and Novo Nordisk A/S ($NVO) are positioned to benefit from this potential market expansion.
ABC Safe Drug Act
The ABC Safe Drug Act, S. 1407, is in early legislative stages, having been referred to the Senate Committee on Finance. This bill aims to restrict federal health programs from purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Recent market data shows mixed performance among major pharmaceutical companies, with $PFE, $MRK, $JNJ, $LLY, and $AMGN all experiencing negative 7-day changes.
Biosimilar Red Tape Elimination Act
The Biosimilar Red Tape Elimination Act, HR5526, if enacted, would automatically grant interchangeability to biosimilar products, reducing market exclusivity for innovator biologic manufacturers. This bill is in the early stages, having been referred to the House Committee on Energy and Commerce on September 19, 2025. Innovator biologic manufacturers like Amgen, Johnson & Johnson, and Biogen face potential market share erosion, while biosimilar producers like Viatris and Teva could benefit.
Small Biotech Innovation Act
The Small Biotech Innovation Act (HR3731) is in an early legislative stage, aiming to exempt research and development-intensive small biotech manufacturers from Medicare drug price negotiations. While the bill could protect future revenue streams for qualifying small biotech firms, there is no direct market reaction evident in the provided stock data for either large or small biotech firms.
Live Charts
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.